Skip to Content
Merck
  • High prevalence of ST131 isolates producing CTX-M-15 and CTX-M-14 among extended-spectrum-beta-lactamase-producing Escherichia coli isolates from Canada.

High prevalence of ST131 isolates producing CTX-M-15 and CTX-M-14 among extended-spectrum-beta-lactamase-producing Escherichia coli isolates from Canada.

Antimicrobial agents and chemotherapy (2010-01-06)
Gisele Peirano, David Richardson, Jana Nigrin, Allison McGeer, Vivian Loo, Baldwin Toye, Michelle Alfa, Colette Pienaar, Pamela Kibsey, Johann D D Pitout
ABSTRACT

Phenotypic and genotypic methods were used to characterize extended-spectrum-beta-lactamase (ESBL)-producing Escherichia coli isolated in 2007 from 11 different Canadian medical centers. Of the 209 ESBL-producing E. coli isolates tested, 148 (71%) produced CTX-M-15, 17 (8%) produced CTX-M-14, 5 (2%) produced CTX-M-3, and 1 produced CTX-M-27. Overall, 96 (46%) of the ESBL producers belonged to clonal complex ST131, with the highest prevalence in Brampton, Calgary, and Winnipeg. ST131 is an important cause of community onset urinary tract infections due to ESBL-producing E. coli across Canada.

MATERIALS
Product Number
Brand
Product Description

Supelco
Nitrofurantoin, VETRANAL®, analytical standard
Sigma-Aldrich
Nitrofurantoin, 98.0-102.0% (EP, UV)
Supelco
Ciprofloxacin, VETRANAL®, analytical standard
Sigma-Aldrich
Ciprofloxacin, ≥98% (HPLC)